The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Body mass index (BMI) as a prelude to hepatocellular carcinoma (HCC) and metabolic dysfunction–associated steatohepatitis (MASH) risk factors in patients with no identified risk factor for developing hepatocellular carcinoma (HCC).
 
Layal Al Mahmasani
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Amitabh Srivastava
No Relationships to Disclose
 
Joanne F. Chou
Stock and Other Ownership Interests - PAIGE.AI (Inst)
Patents, Royalties, Other Intellectual Property - Company Paige.AI MSK has licensed intellectual property related to digital pathology slides and algorithm development to Paige. MSK also holds equity in Paige. AI. (Inst)
 
Jinru Shia
Consulting or Advisory Role - PAIGE.AI
 
Imane H. El Dika
No Relationships to Disclose
 
Amin Yaqubie
No Relationships to Disclose
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Elevar Therapeutics; Exelixis; Hepion Pharmaceuticals; Imvax; Jazz Pharmaceuticals; Lilly; Medivir; Merck; QED Therapeutics; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Codiak Biosciences (Inst); Debiopharm Group (Inst); Genoscience Pharma (Inst); Genoscience Pharma (Inst); Incyte (Inst); Kinnate Biopharma; Lilly (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
Eileen M. O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); SERVIER (I); Tempus; Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Abbvie; AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Eisai; Exelixis; Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Neogene Therapeutics (I); Novartis (I); QED Therapeutics; Roche/Genentech; Servier; Tempus (I); Vector Health; Yiviva
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)